- Home
- BCDA vs CNFR Comparison
BCDA vs CNFR Comparison
Compare BCDA & CNFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- CNFR
- Stock Information
- Founded
- BCDA N/A
- CNFR 2009
- Country
- BCDA United States
- CNFR United States
- Employees
- BCDA N/A
- CNFR N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- CNFR Property-Casualty Insurers
- Sector
- BCDA Health Care
- CNFR Finance
- Exchange
- BCDA Nasdaq
- CNFR Nasdaq
- Market Cap
- BCDA 11.3M
- CNFR 9.9M
- IPO Year
- BCDA N/A
- CNFR 2015
- Fundamental
- Price
- BCDA $1.56
- CNFR $1.82
- Analyst Decision
- BCDA Strong Buy
- CNFR
- Analyst Count
- BCDA 1
- CNFR 0
- Target Price
- BCDA $25.00
- CNFR N/A
- AVG Volume (30 Days)
- BCDA 46.4K
- CNFR 2.4M
- Earning Date
- BCDA 11-12-2025
- CNFR 11-12-2025
- Dividend Yield
- BCDA N/A
- CNFR N/A
- EPS Growth
- BCDA N/A
- CNFR N/A
- EPS
- BCDA N/A
- CNFR 2.45
- Revenue
- BCDA N/A
- CNFR $52,654,000.00
- Revenue This Year
- BCDA N/A
- CNFR $25.91
- Revenue Next Year
- BCDA N/A
- CNFR N/A
- P/E Ratio
- BCDA N/A
- CNFR $0.46
- Revenue Growth
- BCDA N/A
- CNFR N/A
- 52 Week Low
- BCDA $1.63
- CNFR $0.42
- 52 Week High
- BCDA $3.25
- CNFR $2.20
- Technical
- Relative Strength Index (RSI)
- BCDA 30.27
- CNFR 84.85
- Support Level
- BCDA $2.11
- CNFR $0.86
- Resistance Level
- BCDA $2.29
- CNFR $2.21
- Average True Range (ATR)
- BCDA 0.12
- CNFR 0.20
- MACD
- BCDA -0.03
- CNFR 0.12
- Stochastic Oscillator
- BCDA 0.96
- CNFR 82.64
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About CNFR Conifer Holdings Inc.
Conifer Holdings Inc is an insurance holding company. The company markets and services the product offerings of the company through specialty personal insurance business lines. The company offers insurance products in Texas, Illinois, and Indiana for homeowners lines and Nevada and Michigan for other lines. The revenues of the company are derived from premiums earned from insurance operations.